Guía de Práctica Clínica sobre la Atención Integral a las Personas ...

193. Llop R, Aguilera C, Bosch M, Espinasa J. Updating of the pharmacologicaltreatment of dementia. Atención Primaria. 2006; 37(2): 108-12.194. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S,Gergel I. Memantine treatment in patients with moderate to severeAlzheimer disease already receiving donepezil: a randomized controlledtrial. JAMA. 2004; 291(3): 317-24.195. Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR,et al. Recommendations for best practices in the treatment ofAlzheimer’s disease in managed care. Am J Geriatr Pharmacother.2006; 4 Suppl A: S9-S24.196. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantinetreatment in patients with mild to moderate Alzheimer’s disease alreadyreceiving a cholinesterase inhibitor: a randomized, double-blind,placebo-controlled trial. Curr Alzheimer Res. 2008; 5(1): 83-9.197. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD.Open-label, multicenter, phase 3 extension study of the safety and efficacyof donepezil in patients with Alzheimer disease. Arch Neurol.2001; 58(3): 427-33.198. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP,et al. Rivastigmine for dementia associated with Parkinson’s disease. NEngl J Med. 2004; 351(24): 2509-18.199. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitiveimpairment in Parkinson’s disease: a randomised controlled study. JNeurol Neurosurg Psychiatry. 2002; 72(6): 708-12.200. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al.Randomized placebo-controlled trial of donepezil in cognitive impairmentin Parkinson’s disease. Int J Geriatr Psychiatry. 2004; 19(1): 1-8.201. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, etal. Donepezil for dementia in Parkinson’s disease: a randomised, doubleblind, placebo controlled, crossover study. J Neurol NeurosurgPsychiatry. 2005; 76(7): 934-9.202. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, KossakowskiK, et al. Memantine in patients with Parkinson’s disease dementia ordementia with Lewy bodies: a double-blind, placebo-controlled, multicentretrial. Lancet Neurol. 2009; 8(7): 613-8.203. McKeith I, Del ST, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacyof rivastigmine in dementia with Lewy bodies: a randomised, double-blind,placebo-controlled international study. Lancet. 2000;356(9247): 2031-6.204. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del ST, Spano PF, et al.Effects of rivastigmine on cognitive function in dementia with lewy bodies:a randomised placebo-controlled international study using the308 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS